US Patent

US8415363 — Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Method of Use · Assigned to Novartis AG · Expires 2026-07-18 · 0y remaining

Vulnerability score 85/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects crystalline forms of the free base and salts of a specific compound used in the preparation of Nilotinib Hydrochloride.

USPTO Abstract

Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base and salts thereof are prepared by various processes.

Drugs covered by this patent

nilotinib-hydrochloride (Nilotinib Hydrochloride) · Jan Beumer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1407`	—	nilotinib-hydrochloride
`U-1407`	—	nilotinib-hydrochloride
`U-1407`	—	nilotinib-hydrochloride

Patent Metadata

Patent number: US8415363
Jurisdiction: US
Classification: Method of Use
Expires: 2026-07-18
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.